Boehringer Ingelheim employees across the U.S. are out in their communities making a difference to help improve the lives of those who have been impacted by the coronavirus.
Boehringer Ingelheim steps up its commitment to sustainable development, building on its historical success in addressing unmet health needs and increasing its ambitions to tackle global health and societal challenges.
New collaboration to improve the detection of type 2 diabetes in high-risk patients starts in Montreal, Quebec
The project will use artificial intelligence (A.I.), wearable technologies and electronic health record systems to identify patients who may have type 2 diabetes in Montreal, Quebec
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.